New drug ALN-ANG3 targets high cholesterol in early human trial
NCT ID NCT06452771
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage study tests an experimental drug called ALN-ANG3 in healthy adults with high cholesterol and triglycerides. The main goal is to check safety and side effects, not yet to see if it works. About 59 participants will receive either the drug or a placebo, and researchers will monitor how the body processes the drug.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ALN-ANG3
- What this could lead to
- If successful, this could lead to a new treatment for high cholesterol and triglycerides, potentially reducing heart disease risk.
- What could go wrong
- This is an early Phase 1 trial focused on safety, not effectiveness. The drug may cause side effects or fail to lower lipids in later studies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS WITH HYPERLIPIDEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
New Zealand Clinical Research
Christchurch, Canterbury, 8013, New Zealand